Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis

NCT02507570 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Prostate Carcinoma Metastatic to the Bone

Interventions

DRUG: Enzalutamide
RADIATION: Radium ra 223 dichloride

Sponsor

Carolina Research Professionals, LLC

Collaborators

[object Object]